Updates are available Correction dated 2024-08-14
Click to view Correction: https://doi.org/10.1038/s41593-024-01752-x
-
Authors
Parhizkar, Samira https://orcid.org/0000-0001-5807-190X
Arzberger, Thomas
Brendel, Matthias
Kleinberger, Gernot
Deussing, Maximilian
Focke, Carola
Nuscher, Brigitte
Xiong, Monica https://orcid.org/0000-0002-8398-1814
Ghasemigharagoz, Alireza
Katzmarski, Natalie
Krasemann, Susanne
Lichtenthaler, Stefan F.
Müller, Stephan A.
Colombo, Alessio
Monasor, Laura Sebastian
Tahirovic, Sabina https://orcid.org/0000-0003-4403-9559
Herms, Jochen
Willem, Michael
Pettkus, Nadine
Butovsky, Oleg
Bartenstein, Peter
Edbauer, Dieter https://orcid.org/0000-0002-7186-4653
Rominger, Axel
Ertürk, Ali https://orcid.org/0000-0001-5163-5100
Grathwohl, Stefan A.
Neher, Jonas J. https://orcid.org/0000-0003-1346-8924
Holtzman, David M.
Meyer-Luehmann, Melanie https://orcid.org/0000-0003-3661-2220
Haass, Christian https://orcid.org/0000-0002-4869-1627
- License Information
-
More Information
Article History
Received: 19 January 2018
Accepted: 14 November 2018
First Online: 7 January 2019
Change Date: 14 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41593-024-01752-x
Competing interests
: C.H. collaborates with Denali and received a speaker honorarium of Roche and Novartis. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. consults for Denali, Eli Lilly, Glaxosmithkline, and AbbVie. A.R. received consultant and speaker honoria from Piramal Imaging and GE Healthcare. O.B. collaborates with Sanofi. S.T. collaborates with Ono Pharmaceuticals (Japan). S.A.G is an employee of Neurimmune AG. All other authors declare no competing interests.
